Psilocybin trials show poorer control group outcomes compared to SSRIs and esketamine, potentially inflating perceived efficacy due to expectancy bias and functional unblinding. Control group response ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback